ES2403107T3 - Método de tratamiento de insuficiencia y deficiencia de vitamina D - Google Patents
Método de tratamiento de insuficiencia y deficiencia de vitamina D Download PDFInfo
- Publication number
- ES2403107T3 ES2403107T3 ES08837933T ES08837933T ES2403107T3 ES 2403107 T3 ES2403107 T3 ES 2403107T3 ES 08837933 T ES08837933 T ES 08837933T ES 08837933 T ES08837933 T ES 08837933T ES 2403107 T3 ES2403107 T3 ES 2403107T3
- Authority
- ES
- Spain
- Prior art keywords
- vitamin
- supplement
- hydroxyvitamin
- administration
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 43
- 206010047626 Vitamin D Deficiency Diseases 0.000 title claims description 20
- 230000007812 deficiency Effects 0.000 title claims description 11
- 238000000034 method Methods 0.000 title description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 136
- 239000013589 supplement Substances 0.000 claims abstract description 131
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical group C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 claims abstract description 122
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 claims abstract description 117
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 claims abstract description 117
- KJKIIUAXZGLUND-ICCVIKJNSA-N 25-hydroxyvitamin D2 Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C KJKIIUAXZGLUND-ICCVIKJNSA-N 0.000 claims abstract description 97
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 62
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 61
- 229940021056 vitamin d3 Drugs 0.000 claims abstract description 61
- 235000005282 vitamin D3 Nutrition 0.000 claims abstract description 60
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims abstract description 56
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims abstract description 55
- 229960002061 ergocalciferol Drugs 0.000 claims abstract description 55
- 235000001892 vitamin D2 Nutrition 0.000 claims abstract description 55
- 239000011653 vitamin D2 Substances 0.000 claims abstract description 55
- 239000003814 drug Substances 0.000 claims abstract description 21
- 229930003316 Vitamin D Natural products 0.000 claims description 76
- 235000019166 vitamin D Nutrition 0.000 claims description 76
- 239000011710 vitamin D Substances 0.000 claims description 76
- 229940046008 vitamin d Drugs 0.000 claims description 76
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 73
- 210000002966 serum Anatomy 0.000 claims description 68
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 claims description 50
- 235000021318 Calcifediol Nutrition 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 35
- 230000001988 toxicity Effects 0.000 claims description 32
- 231100000419 toxicity Toxicity 0.000 claims description 32
- 238000011260 co-administration Methods 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 8
- 230000002503 metabolic effect Effects 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 3
- 230000000144 pharmacologic effect Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 36
- 239000011575 calcium Substances 0.000 description 34
- 229910052791 calcium Inorganic materials 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 238000009472 formulation Methods 0.000 description 18
- 229940088597 hormone Drugs 0.000 description 17
- 239000005556 hormone Substances 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 241000700159 Rattus Species 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 230000036765 blood level Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 208000037147 Hypercalcaemia Diseases 0.000 description 8
- 238000011887 Necropsy Methods 0.000 description 8
- 102000003982 Parathyroid hormone Human genes 0.000 description 8
- 108090000445 Parathyroid hormone Proteins 0.000 description 8
- 229960005084 calcitriol Drugs 0.000 description 8
- 230000000148 hypercalcaemia Effects 0.000 description 8
- 208000030915 hypercalcemia disease Diseases 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 239000000199 parathyroid hormone Substances 0.000 description 8
- 229960001319 parathyroid hormone Drugs 0.000 description 8
- 102000009310 vitamin D receptors Human genes 0.000 description 8
- 108050000156 vitamin D receptors Proteins 0.000 description 8
- 235000020964 calcitriol Nutrition 0.000 description 7
- 239000011612 calcitriol Substances 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 208000005368 osteomalacia Diseases 0.000 description 6
- 239000011574 phosphorus Substances 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 208000007442 rickets Diseases 0.000 description 6
- 102100027518 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 101000861278 Homo sapiens 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Proteins 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000004731 jugular vein Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010020590 Hypercalciuria Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 238000001631 haemodialysis Methods 0.000 description 4
- 230000000322 hemodialysis Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- -1 vitamin D compounds Chemical class 0.000 description 4
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010021135 Hypovitaminosis Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940069978 calcium supplement Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 231100000161 signs of toxicity Toxicity 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 208000005475 Vascular calcification Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000012754 cardiac puncture Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 201000005991 hyperphosphatemia Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019195 vitamin supplement Nutrition 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- BPEQZNMKGFTMQE-LXHCYJFYSA-N (e,3r,6r)-6-[(1r,3as,4e,7ar)-4-[(2z)-2-[(5s)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-1-yl]-2,3-dimethylhept-4-ene-2,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@@](C)(O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C BPEQZNMKGFTMQE-LXHCYJFYSA-N 0.000 description 1
- ZGLHBRQAEXKACO-XJRQOBMKSA-N 1alpha,25-dihydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C ZGLHBRQAEXKACO-XJRQOBMKSA-N 0.000 description 1
- YPFNIPKMNMDDDB-UHFFFAOYSA-K 2-[2-[bis(carboxylatomethyl)amino]ethyl-(2-hydroxyethyl)amino]acetate;iron(3+) Chemical compound [Fe+3].OCCN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O YPFNIPKMNMDDDB-UHFFFAOYSA-K 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101150104085 Cyp24a1 gene Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021024 Hypolipidaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
- 201000010859 Milk allergy Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101710188106 SEC14-like protein 2 Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010053260 Secondary hyperthyroidism Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 238000007681 bariatric surgery Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 208000018339 bone inflammation disease Diseases 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000002092 calcimimetic effect Effects 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013341 fat substitute Nutrition 0.000 description 1
- 239000003778 fat substitute Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 201000006409 renal osteodystrophy Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91384907P | 2007-04-25 | 2007-04-25 | |
| US913849P | 2007-04-25 | ||
| PCT/IB2008/003480 WO2009047644A2 (en) | 2007-04-25 | 2008-04-25 | Method of treating vitamin d insufficiency and deficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2403107T3 true ES2403107T3 (es) | 2013-05-14 |
Family
ID=40445280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08837933T Active ES2403107T3 (es) | 2007-04-25 | 2008-04-25 | Método de tratamiento de insuficiencia y deficiencia de vitamina D |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11752158B2 (Direct) |
| EP (1) | EP2148684B1 (Direct) |
| JP (2) | JP5444212B2 (Direct) |
| KR (1) | KR101495578B1 (Direct) |
| CN (2) | CN104257667B (Direct) |
| CA (1) | CA2683628C (Direct) |
| DK (1) | DK2148684T3 (Direct) |
| ES (1) | ES2403107T3 (Direct) |
| PL (1) | PL2148684T3 (Direct) |
| PT (1) | PT2148684E (Direct) |
| WO (1) | WO2009047644A2 (Direct) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3103745B2 (ja) | 1995-05-24 | 2000-10-30 | 松下電器産業株式会社 | 高周波加熱装置 |
| US8404667B2 (en) * | 2006-12-29 | 2013-03-26 | Wisconsin Alumni Research Foundation | Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog |
| NZ555277A (en) * | 2004-11-22 | 2010-12-24 | Wisconsin Alumni Res Found | 2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses |
| CA2640094C (en) | 2006-02-03 | 2015-04-14 | Proventiv Therapeutics, Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
| PL2679228T3 (pl) | 2006-06-21 | 2018-07-31 | Opko Ireland Global Holdings, Ltd. | Terapia z użyciem środka do uzupełniania witaminy D i środka do zastępowania hormonami witaminy D |
| FI3225243T3 (fi) | 2007-04-25 | 2025-10-13 | Opko Renal Llc | Menetelmä sekundaarisen hyperparatyreoosin turvalliseen ja tehokkaaseen hoitoon ja ehkäisyyn kroonisen munuaistaudin yhteydessä |
| SI2481400T1 (sl) | 2007-04-25 | 2014-11-28 | Opko IP Holdings II, Inc. | Nadzorovano oralno sproščanje sestavkov, ki vsebujejo spojino vitamina D in voskasti nosilec |
| KR101495578B1 (ko) | 2007-04-25 | 2015-02-25 | 사이토크로마 인코포레이티드 | 비타민 ｄ 부족 및 결핍의 치료 방법 |
| MX2010008894A (es) * | 2008-02-13 | 2010-11-05 | Dsm Ip Assets Bv | Combinacion de vitamina d y 25-hidroxi-vitamina d3. |
| EP2249842B2 (en) | 2008-02-13 | 2025-03-05 | DSM IP Assets B.V. | Use of 25-hydroxy-vitamin d3 and vitamin d to affect human muscle physiology |
| EP3112476B1 (en) | 2008-04-02 | 2023-08-02 | EirGen Pharma Ltd. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
| CA2731382C (en) * | 2008-07-24 | 2020-04-28 | Wisconsin Alumni Research Foundation | Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration |
| US20100331412A1 (en) * | 2009-03-30 | 2010-12-30 | Patricia Lawler Kenet | Two container skin care product |
| US8518917B2 (en) * | 2009-10-02 | 2013-08-27 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-vitamin D analogs and their uses |
| EP3636280B1 (en) | 2010-03-29 | 2025-05-14 | EirGen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| TR201902517T4 (tr) * | 2010-12-06 | 2019-03-21 | Dsm Ip Assets Bv | 25-hidroksivitamin D3 ile artan eotaksin ile ilişkilendirilen durumların tedavi edilmesi. |
| CN103141433A (zh) * | 2013-03-07 | 2013-06-12 | 青岛农业大学 | 维生素a临界缺乏家禽动物模型的构建方法 |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| US10220047B2 (en) * | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| MX2017001751A (es) * | 2014-08-07 | 2017-05-30 | Opko Ireland Global Holdings Ltd | Terapia adjuntiva con 25-hidroxi vitamina d. |
| US20160131574A1 (en) * | 2014-11-06 | 2016-05-12 | The Chinese University Of Hong Kong | Method for screening vitamin d insufficiency using skin colourimetry |
| EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
| EP3377077A1 (en) * | 2015-11-20 | 2018-09-26 | Nestec S.A. | Methods using whey protein to improve or maintain muscle quality |
| SG10201913863TA (en) | 2016-03-28 | 2020-03-30 | Opko Ireland Global Holdings Limited | Methods of vitamin d treatment |
| JP7590184B2 (ja) | 2018-04-03 | 2024-11-26 | オプコ アイルランド グローバル ホールディングス リミテッド | 肥満外科手術患者におけるカルシフェジオールの使用 |
| EP3920938A1 (en) * | 2019-02-06 | 2021-12-15 | EirGen Pharma Ltd. | Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein |
| EP3708171A1 (en) * | 2019-03-11 | 2020-09-16 | Roger Bouillon | Treatment of vitamin d deficiency with 25(oh) vitamin d in critically ill patients |
| CN115397432A (zh) * | 2020-04-07 | 2022-11-25 | 卡博金艾美斯有限公司 | 25-羟基维生素d2和/或d3用于肥胖症 |
| CN114748486A (zh) * | 2022-03-25 | 2022-07-15 | 南京盛德生物科技研究院有限公司 | 一种含有维生素k2改善心血管钙化的药物组合物及其制备方法与应用 |
| WO2025094144A1 (en) | 2023-11-02 | 2025-05-08 | Eirgen Pharma Ltd. | Controlling loss of kidney function |
Family Cites Families (250)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3565924A (en) * | 1968-07-01 | 1971-02-23 | Wisconsin Alumni Res Found | 25-hydroxycholfcalciferol |
| US3833622A (en) | 1969-03-17 | 1974-09-03 | Upjohn Co | Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds |
| US3974272A (en) | 1972-09-01 | 1976-08-10 | Merck & Co., Inc. | Palatable cholestyramine coacervate compositions |
| US3880894A (en) * | 1974-05-24 | 1975-04-29 | Wisconsin Alumni Res Found | 1,25-Dihydroxyergocalciferol |
| US4004003A (en) * | 1974-08-28 | 1977-01-18 | The Upjohn Company | 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis |
| US4230701A (en) * | 1979-03-21 | 1980-10-28 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
| US4335120A (en) * | 1979-03-21 | 1982-06-15 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
| JPS55139320A (en) | 1979-04-16 | 1980-10-31 | Teijin Ltd | Bone metabolism regulator |
| US4338312A (en) * | 1981-05-11 | 1982-07-06 | Wisconsin Alumni Research Foundation | Method for preventing parturient paresis in dairy cattle |
| JPS57188520A (en) | 1981-05-15 | 1982-11-19 | Kureha Chem Ind Co Ltd | Antihyperkalemia |
| US4442093A (en) | 1981-05-15 | 1984-04-10 | Kureha Kagaku Kogyo Kabushiki Kaisha | Method for administering 24,25-dihydroxycholecalciferol to persons suffering from hypercalcemia |
| JPS5832823A (ja) * | 1981-08-20 | 1983-02-25 | Chugai Pharmaceut Co Ltd | 脱癌剤 |
| JPS58206524A (ja) | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| US4448721A (en) | 1982-09-20 | 1984-05-15 | Wisconsin Alumni Research Foundation | Hydroxyvitamin D2 compounds and process for preparing same |
| US4721613A (en) * | 1982-12-13 | 1988-01-26 | Alza Corporation | Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use |
| JPS59155309A (ja) * | 1983-02-22 | 1984-09-04 | Teijin Ltd | 活性型ビタミンｄ↓３類組成物 |
| US4684524A (en) * | 1984-03-19 | 1987-08-04 | Alza Corporation | Rate controlled dispenser for administering beneficial agent |
| US4555364A (en) * | 1984-11-01 | 1985-11-26 | Wisconsin Alumni Research Foundation | Method for preparing 1-hydroxyvitamin D compounds |
| US4695591A (en) * | 1985-03-29 | 1987-09-22 | Schering Corporation | Controlled release dosage forms comprising hydroxypropylmethylcellulose |
| US4668517A (en) * | 1985-04-04 | 1987-05-26 | Norwich Eaton Pharmaceuticals, Inc. | Furazolidone dosage form |
| EP0207638B1 (en) * | 1985-06-04 | 1990-12-19 | Teijin Limited | Sustained-release pharmaceutical preparation |
| JPS61293911A (ja) | 1985-06-24 | 1986-12-24 | Teisan Seiyaku Kk | 徐放化製剤 |
| US5167965A (en) | 1987-02-09 | 1992-12-01 | The Dow Chemical Company | Palatable cholestyramine granules, tablets and methods for preparation thereof |
| US4892821A (en) | 1987-07-08 | 1990-01-09 | Taisho Pharmaceutical Co., Ltd. | Method for preparing vitamin D compounds |
| US4997824A (en) | 1987-07-22 | 1991-03-05 | Teva Pharmaceutical Industries Ltd. | Combination of cholecalciferol derivatives for the treatment of renal bone disease |
| US5869473A (en) * | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US5104864A (en) * | 1988-08-02 | 1992-04-14 | Bone Care International, Inc. | Method for treating and preventing loss of bone mass |
| CA1341408C (en) * | 1988-08-02 | 2002-12-10 | Charles W. Bishop | Method for treating and preventing loss of bone mass |
| US5602116A (en) * | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| JP2893191B2 (ja) * | 1988-11-08 | 1999-05-17 | 武田薬品工業株式会社 | 放出制御性マトリックス剤 |
| JP2525478B2 (ja) | 1989-03-01 | 1996-08-21 | 帝人株式会社 | 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤 |
| JPH02240024A (ja) | 1989-03-13 | 1990-09-25 | Ss Pharmaceut Co Ltd | 活性型ビタミンｄ↓３類製剤用組成物 |
| US5026559A (en) * | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
| GB9004544D0 (en) | 1990-03-01 | 1990-04-25 | Leo Pharm Prod Ltd | Novel treatment ii |
| JP2845342B2 (ja) | 1990-04-28 | 1999-01-13 | 大正製薬株式会社 | ビタミンｄ▲下３▼誘導体含有固形製剤組成物 |
| JPH04198129A (ja) | 1990-11-28 | 1992-07-17 | Sumitomo Pharmaceut Co Ltd | 活性型ビタミンｄ↓３類含有組成物 |
| JP2893140B2 (ja) | 1990-11-30 | 1999-05-17 | エスエス製薬株式会社 | 安定なビタミンｄ製剤 |
| JPH04288016A (ja) | 1991-03-14 | 1992-10-13 | Tokai Capsule Kk | 活性型ビタミンｄ３類軟カプセル剤の製造方法 |
| DE69214704T2 (de) | 1991-04-09 | 1997-04-17 | Takeda Chemical Industries Ltd | Stabilisiertes Vitamin D Arzneimittel |
| US5693615A (en) * | 1991-06-05 | 1997-12-02 | The Procter & Gamble Company | Therapeutic compositions for osteoinduction |
| SK136693A3 (en) * | 1991-06-05 | 1994-10-05 | Procter & Gamble | Therapeutic compositions for osteoinduction |
| US6001884A (en) | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| US5160742A (en) * | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
| ATE141914T1 (de) * | 1992-05-20 | 1996-09-15 | Hoffmann La Roche | Fluorierte analoge vitamins d3 |
| ES2170069T3 (es) | 1992-06-22 | 2002-08-01 | Bone Care Int Inc | 1-alfa-hidroxiprevitamina d para administracion oral. |
| US5795882A (en) | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
| US5354743A (en) | 1992-09-15 | 1994-10-11 | Thys Jacobs Susan | Method for the treatment of premenstrual syndrome with vitamin D |
| US5431917A (en) | 1992-10-08 | 1995-07-11 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
| US5342626A (en) | 1993-04-27 | 1994-08-30 | Merck & Co., Inc. | Composition and process for gelatin-free soft capsules |
| JP2684587B2 (ja) | 1993-06-21 | 1997-12-03 | 呉羽化学工業株式会社 | 腎性骨異栄養症における骨量減少抑制剤 |
| US6121469A (en) | 1993-12-23 | 2000-09-19 | The Regents Of The University Of California | Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs |
| JPH07242550A (ja) | 1994-03-02 | 1995-09-19 | Teijin Ltd | 二次性副甲状腺機能亢進症治療剤 |
| IL110117A0 (en) | 1994-06-24 | 1994-10-07 | Univ Ben Gurion | Pharmaceutical compositions comprising vitamin-d analogs |
| SE9402422D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New beads for controlled release and a pharmaceutical preparation containing the same |
| EP0769936A1 (en) | 1994-07-22 | 1997-05-02 | G.D. Searle & Co. | Self-emulsifying drug delivery system |
| JPH0892098A (ja) | 1994-09-27 | 1996-04-09 | Teijin Ltd | 肺結核治療剤 |
| DE69533948T2 (de) | 1994-10-21 | 2005-12-15 | NPS Pharmaceuticals, Inc., Salt Lake City | Kalzium-Rezeptor aktive Verbindungen |
| US5756123A (en) | 1994-12-01 | 1998-05-26 | Japan Elanco Co., Ltd. | Capsule shell |
| US20020183288A1 (en) | 1995-04-03 | 2002-12-05 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US20040043971A1 (en) * | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
| US6242434B1 (en) | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
| US6376479B1 (en) * | 1995-04-03 | 2002-04-23 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| WO1997011053A1 (en) | 1995-09-21 | 1997-03-27 | Wisconsin Alumni Research Foundation | Calcitriol derivatives and their uses |
| DE19549243A1 (de) | 1995-12-21 | 1997-06-26 | Schering Ag | Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga |
| US5939408A (en) | 1996-05-23 | 1999-08-17 | Hoffman-La Roche Inc. | Vitamin D3 analogs |
| NO971934L (no) | 1996-05-23 | 1997-11-24 | Hoffmann La Roche | Flourinerte vitamin D3 -analoger |
| DE69716469T2 (de) * | 1996-08-26 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol |
| US5958451A (en) | 1996-09-03 | 1999-09-28 | Yung Shin Pharm Ind. Co., Ltd. | Process for producing porous, controlled-release capsules and encapsulated composition |
| US5976784A (en) * | 1996-09-20 | 1999-11-02 | Wisconsin Alumni Research Foundation | Calcitriol derivatives and their uses |
| US8828432B2 (en) | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
| EP0935523B1 (en) | 1996-10-28 | 2004-09-29 | Inc. General Mills | Embedding and encapsulation of controlled release particles |
| JPH10158171A (ja) | 1996-12-02 | 1998-06-16 | Kita:Kk | ビタミンｄ化合物を配合した眼内投与剤 |
| US20020128240A1 (en) | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
| US6503893B2 (en) | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
| US20030129194A1 (en) | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
| US6034075A (en) | 1997-03-20 | 2000-03-07 | The Trustees Of Columbia University In The City Of New York | Method of treating polycystic ovarian syndrome |
| US5872113A (en) | 1997-05-16 | 1999-02-16 | Syntex (U.S.A.) Inc. | Fluorinated vitamin D3 analogs |
| DK1009387T3 (da) | 1997-07-02 | 2006-08-14 | Euro Celtique Sa | Stabiliserede tramadolformuleringer med langvarig frigivelse |
| JPH1175863A (ja) | 1997-07-10 | 1999-03-23 | Kyowa Hakko Kogyo Co Ltd | ２５−ヒドロキシビタミンＤ３−１α−水酸化酵素および該酵素をコードするＤＮＡ |
| US6096876A (en) | 1997-08-06 | 2000-08-01 | Shriners Hospitals For Children | 1-α-hydroxylase materials and methods |
| US20020076442A1 (en) | 1997-09-02 | 2002-06-20 | Martin Burke | Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders |
| US5919986A (en) | 1997-10-17 | 1999-07-06 | Hoffmann-La Roche Inc. | D-homo vitamin D3 derivatives |
| JPH11158074A (ja) | 1997-12-03 | 1999-06-15 | Hayashi Tomie | 高アミノ酸付加活性型ビタミンｄ強化組成物 |
| US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
| CN1301298A (zh) | 1998-03-25 | 2001-06-27 | 卡坦诺根公司 | 用于预防和治疗癌症的方法 |
| ATE515265T1 (de) | 1998-03-27 | 2011-07-15 | Univ Oregon Health & Science | Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen |
| US6197340B1 (en) | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
| US8133694B2 (en) | 1998-06-25 | 2012-03-13 | Immundiagnostik Ag | Functional vitamin D derivatives and method of determining 25-hydroxy- and 1α, 25-dihydroxy vitamin D |
| US6214376B1 (en) | 1998-08-25 | 2001-04-10 | Banner Pharmacaps, Inc. | Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture |
| SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| EP1039882B1 (en) | 1998-08-27 | 2010-11-10 | Pfizer Health AB | Therapeutic formulation for administering tolterodine with controlled release |
| US6139875A (en) * | 1998-09-29 | 2000-10-31 | Eastman Chemical Company | Aqueous enteric coating composition and low gastric permeability enteric coating |
| WO2000018374A1 (en) | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
| DK1119345T3 (da) | 1998-10-09 | 2009-08-03 | Gen Mills Inc | Indkapsling af fölsomme flydende bestanddele i en matrix til opnåelse af adskilte opbevaringsstabile partikler |
| JP3449253B2 (ja) | 1998-10-29 | 2003-09-22 | シオノギクオリカプス株式会社 | 硬質カプセルの製造方法 |
| JP2000206312A (ja) | 1998-11-12 | 2000-07-28 | Olympus Optical Co Ltd | 光学素子 |
| ATE260642T1 (de) | 1998-12-17 | 2004-03-15 | Alza Corp | Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen |
| US6342249B1 (en) * | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| US6432936B1 (en) * | 1999-01-20 | 2002-08-13 | Wisconsin Alumni Research Foundation | Crystalline 1α-hydroxyvitamin D2 and method of purification thereof |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| WO2000059513A1 (en) * | 1999-04-01 | 2000-10-12 | Johns Hopkins University | NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1α, 25-DIHYDROXY VITAMIN D¿3? |
| US7648826B1 (en) | 1999-04-02 | 2010-01-19 | The Regents Of The University Of California | Detecting CYP24 expression level as a marker for predisposition to cancer |
| DE19916419B4 (de) | 1999-04-08 | 2005-06-16 | Schering Ag | Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose |
| WO2000072831A1 (en) * | 1999-05-27 | 2000-12-07 | Drugtech Corporation | Nutritional formulations |
| US6340473B1 (en) | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
| US6274169B1 (en) * | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
| US6051567A (en) * | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
| HK1046851A1 (en) | 1999-08-31 | 2003-01-30 | Chugai Seiyaku Kabushiki Kaisha | Soft capsules |
| US20060034937A1 (en) | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| GB0007419D0 (en) * | 2000-03-27 | 2000-05-17 | Smithkline Beecham Gmbh | Composition |
| US6375981B1 (en) | 2000-06-01 | 2002-04-23 | A. E. Staley Manufacturing Co. | Modified starch as a replacement for gelatin in soft gel films and capsules |
| AU2001278956B2 (en) | 2000-07-18 | 2007-04-05 | Genzyme Corporation | Stabilized 1alpha-hydroxy vitamin d |
| US6491950B1 (en) | 2000-08-07 | 2002-12-10 | Kos Pharmaceuticals, Inc. | Controlled release pharmaceutical composition |
| WO2002017848A1 (fr) | 2000-08-29 | 2002-03-07 | Nisshin Kasei Co., Ltd. | Capsule en dur |
| US6887493B2 (en) | 2000-10-25 | 2005-05-03 | Adi Shefer | Multi component controlled release system for oral care, food products, nutraceutical, and beverages |
| JP2004512354A (ja) | 2000-10-30 | 2004-04-22 | ユーロ−セルティーク，エス．エイ． | ヒドロコドン放出制御製剤 |
| US6479649B1 (en) | 2000-12-13 | 2002-11-12 | Fmc Corporation | Production of carrageenan and carrageenan products |
| JP2002302447A (ja) | 2001-04-03 | 2002-10-18 | Shimizu Pharmaceutical Co Ltd | 局所投与用癌治療剤 |
| WO2002092056A1 (en) | 2001-05-15 | 2002-11-21 | Warner-Lambert Company Llc | Compaction process for manufacture of sodium phenytoin dosage form |
| EP1410794A1 (en) | 2001-07-05 | 2004-04-21 | Wakunaga Pharmaceutical Co., Ltd. | Soft capsules |
| US6870833B2 (en) | 2001-07-20 | 2005-03-22 | Net2Phone, Inc. | Active voice messaging |
| US7166585B2 (en) | 2001-08-22 | 2007-01-23 | Cytochroma Inc. | 24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3 |
| US7033996B2 (en) | 2001-08-31 | 2006-04-25 | University Of Medicine & Dentistry Of New Jersey | Method for the treatment of vitamin D related disease |
| DE10149674A1 (de) | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
| CA2463505C (en) * | 2001-10-12 | 2011-07-12 | Johns Hopkins University | Low-calcemic oxime analogs of 1.alpha.,25-dihydroxy vitamin d3 |
| US7056655B2 (en) | 2001-11-02 | 2006-06-06 | Scantibodies Laboratory, Inc. | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| US6524788B1 (en) | 2001-11-02 | 2003-02-25 | Thomas L. Cantor | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| ITMI20012366A1 (it) | 2001-11-09 | 2003-05-09 | Farmatron Ltd | Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali |
| EP1447082B1 (en) | 2001-11-22 | 2010-11-10 | Morishita Jintan Co., Ltd. | Non-gelatinous capsules |
| GB0128415D0 (en) | 2001-11-27 | 2002-01-16 | Univ Sheffield | Medicaments |
| EA008072B1 (ru) | 2001-12-03 | 2007-02-27 | Новацея, Инк. | Фармацевтические составы, содержащие соединения активного витамина d |
| US6627622B2 (en) * | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
| FR2829142B1 (fr) | 2001-12-27 | 2004-02-13 | Ulice | Composition filmogene d'heteroxylanes pour la fabrication de capsules ainsi obtenues |
| US7632518B2 (en) | 2002-01-15 | 2009-12-15 | Dsm Ip Assets B.V. | 25-hydroxy vitamin D3 compositions |
| US6949256B2 (en) | 2002-01-18 | 2005-09-27 | Banner Pharmacaps, Inc. | Non-gelatin capsule shell formulation |
| NO20021592D0 (no) | 2002-04-04 | 2002-04-04 | Fmc Biopolymer As | Polysakkaridkapsler og fremgangsmåte ved fremstilling derav |
| WO2003086415A1 (en) | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| AU2003220689A1 (en) | 2002-04-10 | 2003-10-27 | Miller, Fred H | Multi-phase, multi-compartment capsular system |
| WO2003093459A1 (en) | 2002-05-02 | 2003-11-13 | Cytochroma Inc. | Stable cytochrome p450 24 (cyp24) expressing cell line and methods and uses thereof |
| AU2003233735A1 (en) | 2002-06-13 | 2003-12-31 | Cytochroma Inc. | 24-sulfoximine vitamin d3 compounds |
| ATE482694T1 (de) | 2002-07-05 | 2010-10-15 | Temrel Ltd | Zusammensetzung zur kontrollierten wirkstoffabgabe |
| AR040672A1 (es) | 2002-07-25 | 2005-04-13 | Glaxo Group Ltd | Forma de dosificacion farmaceutica multicomponenete, cuerpo apropiado para ser utilizado en la misma y procedimiento para prepararla |
| ATE373472T1 (de) | 2002-07-29 | 2007-10-15 | Alza Corp | Verfahren und dosierformen für die kontrollierte abgabe von paliperidon |
| US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
| AU2002368245A1 (en) | 2002-09-26 | 2004-04-19 | Young-Kweon Choi | Matrix type patch for transdermal administration of vitamin d analog and the use thereof |
| US20050101576A1 (en) | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
| US8999372B2 (en) | 2002-11-14 | 2015-04-07 | Cure Pharmaceutical Corporation | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
| JP2004175750A (ja) | 2002-11-28 | 2004-06-24 | Kose Corp | 皮膚障害抑制剤、皮膚障害改善剤、及びそれらを含有する皮膚外用剤 |
| US20050026877A1 (en) | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| JP2006514695A (ja) | 2002-12-16 | 2006-05-11 | テバ ファーマシューティカル インダストリーズ リミティド | ビタミンｄ誘導体の前用量投与によってアレンドロネート又は他のビスフォスフォネートの全体利用効率を高める方法 |
| DE20321698U1 (de) | 2002-12-16 | 2008-12-24 | Teva Pharmaceutical Industries Ltd. | Medikament zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin-D-Derivats |
| CA2510228C (en) | 2002-12-18 | 2012-10-30 | Johns Hopkins University | 25-so2-substituted analogs of 1.alpha.,25-dihydroxyvitamin d3 |
| DE602004015246D1 (de) | 2003-02-11 | 2008-09-04 | Alza Corp | Verfahren und dosierformen mit modifizierter schichtgeometrie |
| US7816341B2 (en) | 2003-04-14 | 2010-10-19 | Fmc Corporation | Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom |
| EP1628620A4 (en) | 2003-04-14 | 2010-01-06 | Fmc Corp | HOMOGENEOUS THERMOREVERSIBLES GEL WITH CARRAGEENAN REDUCED VISCOSITY AND PRODUCTS MANUFACTURED THEREOF |
| EP1677802A2 (en) | 2003-04-30 | 2006-07-12 | Bioxell S.p.a. | 1,3 aclyated 24-keto-vitamin d3 compounds and methods of use thereof |
| AU2004247272A1 (en) | 2003-06-16 | 2004-12-23 | Solx, Inc. | Shunt for the treatment of glaucoma |
| CA2530113C (en) | 2003-06-26 | 2013-08-13 | Control Delivery Systems, Inc. | Bioerodible sustained release drug delivery systems |
| AU2003903382A0 (en) | 2003-07-03 | 2003-07-17 | Medvet Science Pty Ltd | Inhibition of calcitriol mediated cyp24 induction screening for compounds therefor and uses thereof |
| JP2007525472A (ja) | 2003-07-04 | 2007-09-06 | ニコメド ダンマーク エイピーエス | 経口使用のための副甲状腺ホルモン（ｐｔｈ）含有医薬組成物 |
| US20050124591A1 (en) * | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
| US20050148557A1 (en) * | 2003-07-29 | 2005-07-07 | Jin Tian | Use of Vitamin Ds to treat kidney disease |
| DK3260117T3 (da) | 2003-09-12 | 2019-07-01 | Amgen Inc | Hurtigt opløsende formulering, der omfatter cinacalcet-hcl |
| US7053075B2 (en) | 2003-11-25 | 2006-05-30 | Deluca Hector F | Methods for reducing body fat using vitamin D compounds |
| US7427670B2 (en) | 2003-12-19 | 2008-09-23 | Cytochroma Inc. | Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof |
| US20060009425A1 (en) | 2004-05-28 | 2006-01-12 | Leticia Delgado-Herrera | Oral formulations of paricalcitol |
| US9750797B2 (en) | 2004-06-16 | 2017-09-05 | Virbac Corporation | Sustained release vaccine composition |
| US20050287213A1 (en) | 2004-06-28 | 2005-12-29 | Wong Patrick S | Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents |
| US20060019933A1 (en) | 2004-07-22 | 2006-01-26 | David Boardman | Process for preparing stabilized vitamin D |
| KR20070043806A (ko) | 2004-07-29 | 2007-04-25 | 사노피-아벤티스 | ｐＨ에 매우 의존적인 용해도를 가지는 활성 성분의 제어방출을 위한 약제학적 다층 정제 |
| US8231896B2 (en) | 2004-11-08 | 2012-07-31 | R.P. Scherer Technologies, Llc | Non-gelatin soft capsule system |
| AU2004325362B2 (en) | 2004-12-03 | 2012-09-06 | Council Of Scientific And Industrial Research | Process of preparation of biodegradable films from semi refined kappa carrageenan |
| US8318210B2 (en) * | 2005-02-28 | 2012-11-27 | Neos Therapeutics, Lp | Compositions and methods of making sustained release liquid formulations |
| US7745226B2 (en) | 2005-04-06 | 2010-06-29 | Quest Diagnostics Investments Incorporated | Methods for detecting vitamin D metabolites |
| PL2985026T3 (pl) | 2005-04-15 | 2023-02-20 | Clarus Therapeutics, Inc. | Farmaceutyczne systemy dostarczania leków hydrofobowych i zawierające je kompozycje |
| US20060257481A1 (en) | 2005-04-21 | 2006-11-16 | Decode Genetics Ehf. | Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy |
| US9205047B2 (en) | 2005-04-25 | 2015-12-08 | The Governing Council Of The University Of Toronto | Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix |
| US20080134937A1 (en) | 2005-05-25 | 2008-06-12 | Joo Hwan Yang | Cellulose hard capsule enhancing mechanical film strength |
| AR055099A1 (es) | 2005-07-28 | 2007-08-08 | Alza Corp | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol |
| DE602006006200D1 (de) | 2005-09-29 | 2009-05-20 | Roche Diagnostics Gmbh | Antikörper gegen 25-hydroxyvitamin d |
| ITFI20050206A1 (it) | 2005-09-30 | 2007-04-01 | Valpharma Sa | Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione |
| WO2007047327A2 (en) * | 2005-10-12 | 2007-04-26 | Proventiv Therapeutics, Llc | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency |
| CA2627351C (en) | 2005-10-26 | 2012-05-01 | Banner Pharmacaps, Inc. | Lipophilic vehicle-based dual controlled release matrix system |
| EP1959935A2 (en) | 2005-10-26 | 2008-08-27 | Banner Pharmacaps Inc. | Hydrophilic vehicle-based dual controlled release matrix system as capsule fill |
| AP2008004489A0 (en) | 2005-11-01 | 2008-06-30 | Cpkelco U S Inc | Films and capsules made from modified carboxymethycellulose materials and methods of making same |
| WO2007068287A1 (en) | 2005-12-15 | 2007-06-21 | Laboratoria Qualiphar | Sustained release vitamin preparation |
| MXPA05014091A (es) | 2005-12-20 | 2007-06-20 | Leopoldo De Jesus Espinosa Abdala | Composiciones farmaceuticas que comprenden derivados de esteroides sinteticos, minerales y el metabolito activo de la vitamina d, 1,25(oh)2d3 (calcitriol) para la prevencion y tratamiento de la osteoporosis y el control de los sintomas de la menopaus |
| WO2007092221A2 (en) | 2006-01-31 | 2007-08-16 | Health Research Inc. | Method for identifying altered vitamin d metabolism |
| US7528122B2 (en) * | 2006-02-02 | 2009-05-05 | Wisconsin Alumni Research Foundation | Vitamin D analog—NEL, methods and uses thereof |
| CA2640094C (en) | 2006-02-03 | 2015-04-14 | Proventiv Therapeutics, Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
| GB0606426D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Benzimidazole derivatives |
| JP2009540053A (ja) | 2006-06-06 | 2009-11-19 | エフ エム シー コーポレーション | カッパー−２カラギーナン組成物及びそれからつくられた製品 |
| US20080109983A1 (en) | 2006-11-10 | 2008-05-15 | Kegel, Llc | Zero Turning Radius Lane Maintenance Machine |
| PL2679228T3 (pl) | 2006-06-21 | 2018-07-31 | Opko Ireland Global Holdings, Ltd. | Terapia z użyciem środka do uzupełniania witaminy D i środka do zastępowania hormonami witaminy D |
| EP1912400A1 (en) | 2006-10-10 | 2008-04-16 | Matsushita Electric Industrial Co., Ltd. | Method and apparatus for mobile IP route optimization |
| KR101170283B1 (ko) | 2006-10-27 | 2012-07-31 | 화이자 프로덕츠 인코포레이티드 | 하이드록시프로필 메틸 셀룰로스 경질 캡슐 및 이의 제조 방법 |
| US8501717B2 (en) | 2007-02-09 | 2013-08-06 | Merck, Sharp & Dohme Corp. | Methods to treat and/or prevent mucositis |
| US8491937B2 (en) | 2007-02-15 | 2013-07-23 | Wyeth Llc | Stability in vitamin and mineral supplements |
| EP2135345A4 (en) | 2007-03-20 | 2016-12-14 | Electrolock Inc | ROEBEL WINDING WITH CONDUCTIVE FELT |
| US20100144679A1 (en) | 2007-03-21 | 2010-06-10 | Duke University | Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture |
| KR101495578B1 (ko) | 2007-04-25 | 2015-02-25 | 사이토크로마 인코포레이티드 | 비타민 ｄ 부족 및 결핍의 치료 방법 |
| CA2684778C (en) | 2007-04-25 | 2017-09-05 | Cytochroma Inc. | Methods and compounds for vitamin d therapy |
| SI2481400T1 (sl) | 2007-04-25 | 2014-11-28 | Opko IP Holdings II, Inc. | Nadzorovano oralno sproščanje sestavkov, ki vsebujejo spojino vitamina D in voskasti nosilec |
| FI3225243T3 (fi) | 2007-04-25 | 2025-10-13 | Opko Renal Llc | Menetelmä sekundaarisen hyperparatyreoosin turvalliseen ja tehokkaaseen hoitoon ja ehkäisyyn kroonisen munuaistaudin yhteydessä |
| US20090004284A1 (en) | 2007-06-26 | 2009-01-01 | Watson Pharmaceuticals, Inc. | Controlled release tamsulosin hydrochloride formulation |
| KR100836960B1 (ko) | 2007-09-07 | 2008-06-10 | 주식회사 서울제약 | 새로운 나이아신 제어방출형 제제 |
| EP2042165A1 (de) | 2007-09-28 | 2009-04-01 | Swiss Caps Rechte und Lizenzen AG | Hot-Melt-Befüllte Weichkapseln |
| WO2009073946A1 (en) | 2007-12-12 | 2009-06-18 | Multi Formulations Ltd. | Particles in a capsule |
| MX2010008894A (es) | 2008-02-13 | 2010-11-05 | Dsm Ip Assets Bv | Combinacion de vitamina d y 25-hidroxi-vitamina d3. |
| KR101579631B1 (ko) | 2008-02-13 | 2015-12-22 | 디에스엠 아이피 어셋츠 비.브이. | 25-하이드록시비타민 ｄ3에 의한 고혈당증 치료 |
| MX2010008896A (es) * | 2008-02-13 | 2010-11-05 | Dsm Ip Assets Bv | Tratamiento de hipertension con 25-hidroxi-vitamina d3. |
| JP5509504B2 (ja) | 2008-02-13 | 2014-06-04 | ディーエスエム アイピー アセッツ ビー．ブイ． | 骨塩密度を改善し、骨粗鬆症を治療するための２５−ヒドロキシ−ビタミンｄ３とビタミンｄ３の併用 |
| EP2249842B2 (en) | 2008-02-13 | 2025-03-05 | DSM IP Assets B.V. | Use of 25-hydroxy-vitamin d3 and vitamin d to affect human muscle physiology |
| EP3112476B1 (en) | 2008-04-02 | 2023-08-02 | EirGen Pharma Ltd. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
| CA2731382C (en) | 2008-07-24 | 2020-04-28 | Wisconsin Alumni Research Foundation | Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration |
| PL2341899T3 (pl) | 2008-09-24 | 2015-05-29 | Evonik Roehm Gmbh | Opioidowa kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu z odpornością na działanie etanolu |
| ES2425762T3 (es) | 2008-10-27 | 2013-10-17 | Roquette Freres | Polímero insoluble en agua: revestimientos de película a base de derivados de almidón modificado para la liberación dirigida al colon |
| SG196810A1 (en) | 2009-01-23 | 2014-02-13 | Acraf | Controlled release pharmaceutical or foodformulation and process for its preparation |
| CH700543A2 (de) | 2009-03-03 | 2010-09-15 | Innogel Ag | Film auf Basis von Stärke. |
| JP5696149B2 (ja) | 2009-09-10 | 2015-04-08 | エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ | シームレスなアルギン酸塩カプセル |
| IT1396937B1 (it) | 2009-11-26 | 2012-12-20 | Bruzzese | Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea |
| FR2953139B1 (fr) | 2009-11-27 | 2012-04-13 | Servier Lab | Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine |
| US8101203B2 (en) | 2010-01-14 | 2012-01-24 | Karl Wei Cao | Hard capsule composition and method of use |
| US8101204B2 (en) | 2010-01-14 | 2012-01-24 | Karl Wei Cao | Hard capsule composition and method of use |
| WO2011095388A1 (en) | 2010-02-04 | 2011-08-11 | Synthon Bv | Tolterodine bead |
| EP3636280B1 (en) | 2010-03-29 | 2025-05-14 | EirGen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| EP2591354B1 (en) | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| KR20120005228A (ko) | 2010-07-08 | 2012-01-16 | 주식회사 네비팜 | 골다공증 치료용 비스포스폰산 함유 장용 약학조성물 및 그의 제조방법 |
| AU2010358565B2 (en) | 2010-08-04 | 2016-07-14 | R.P. Scherer Technologies, Llc | Film-forming composition for soft capsules |
| US20120135103A1 (en) | 2010-11-30 | 2012-05-31 | Mead Johnson Nutrition Company | Staged Infant Feeding Regimen To Promote Healthy Development And Growth |
| TR201902517T4 (tr) | 2010-12-06 | 2019-03-21 | Dsm Ip Assets Bv | 25-hidroksivitamin D3 ile artan eotaksin ile ilişkilendirilen durumların tedavi edilmesi. |
| ES2614817T3 (es) | 2010-12-28 | 2017-06-02 | Future Diagnostics B.V. | Reactivo de liberación para vitamina D |
| GB2502032B (en) | 2011-03-02 | 2015-03-04 | D3 Pharma Ltd | Stable Vitamin D3 Composition |
| WO2012144789A2 (ko) | 2011-04-20 | 2012-10-26 | 주식회사 서흥캅셀 | 붕해도 및 피막 경도를 개선한 비동물성 연질 캡슐 피막 조성물 |
| CN103781487A (zh) | 2011-04-20 | 2014-05-07 | 米科生物公司 | 用于增强免疫应答的组合物和方法 |
| CN102771688A (zh) | 2011-05-13 | 2012-11-14 | 富曼实（上海）商贸有限公司 | 可食用液体填充的多糖胶囊 |
| US20130085121A1 (en) | 2011-09-30 | 2013-04-04 | Jianguo Wang | Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d |
| WO2014029953A1 (en) | 2012-08-21 | 2014-02-27 | Cipla Limited | Hot melt extruded (hme) pharmaceutical composition of cinacalcet |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| PT106978A (pt) | 2013-05-31 | 2014-12-02 | Tecnimede Sociedade Tecnico Medicinal S A | Composição sólida oral contendo ácido ibandrónico e vitamina d |
| EP2815745A1 (en) | 2013-06-21 | 2014-12-24 | Swiss Caps Rechte und Lizenzen AG | Soft shell capsule and process for its manufacture |
| CN103495176B (zh) | 2013-10-26 | 2015-01-28 | 中山市凯博思淀粉材料科技有限公司 | 一种共混挤出法制备淀粉基软胶囊的方法 |
| CN103520133B (zh) | 2013-10-26 | 2015-02-04 | 中山市凯博思淀粉材料科技有限公司 | 一种淀粉基软胶囊的制备方法 |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| MX2017001751A (es) | 2014-08-07 | 2017-05-30 | Opko Ireland Global Holdings Ltd | Terapia adjuntiva con 25-hidroxi vitamina d. |
-
2008
- 2008-04-25 KR KR1020097024309A patent/KR101495578B1/ko active Active
- 2008-04-25 WO PCT/IB2008/003480 patent/WO2009047644A2/en not_active Ceased
- 2008-04-25 EP EP08837933A patent/EP2148684B1/en active Active
- 2008-04-25 PL PL08837933T patent/PL2148684T3/pl unknown
- 2008-04-25 PT PT88379334T patent/PT2148684E/pt unknown
- 2008-04-25 ES ES08837933T patent/ES2403107T3/es active Active
- 2008-04-25 CN CN201410348022.7A patent/CN104257667B/zh active Active
- 2008-04-25 CA CA2683628A patent/CA2683628C/en active Active
- 2008-04-25 US US12/597,230 patent/US11752158B2/en active Active
- 2008-04-25 CN CN200880013367.XA patent/CN101668532B/zh active Active
- 2008-04-25 DK DK08837933.4T patent/DK2148684T3/da active
- 2008-04-25 JP JP2010504912A patent/JP5444212B2/ja active Active
-
2013
- 2013-12-20 JP JP2013264004A patent/JP5855633B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101668532A (zh) | 2010-03-10 |
| HK1205936A1 (en) | 2015-12-31 |
| CA2683628A1 (en) | 2009-04-16 |
| PT2148684E (pt) | 2013-04-19 |
| WO2009047644A3 (en) | 2009-05-28 |
| JP2014055184A (ja) | 2014-03-27 |
| PL2148684T3 (pl) | 2013-06-28 |
| WO2009047644A2 (en) | 2009-04-16 |
| CN104257667B (zh) | 2019-06-04 |
| CN101668532B (zh) | 2014-08-20 |
| KR101495578B1 (ko) | 2015-02-25 |
| DK2148684T3 (da) | 2013-04-22 |
| JP5855633B2 (ja) | 2016-02-09 |
| EP2148684A2 (en) | 2010-02-03 |
| CN104257667A (zh) | 2015-01-07 |
| JP5444212B2 (ja) | 2014-03-19 |
| EP2148684B1 (en) | 2013-01-16 |
| CA2683628C (en) | 2018-03-06 |
| JP2010525050A (ja) | 2010-07-22 |
| KR20100017238A (ko) | 2010-02-16 |
| US20100120728A1 (en) | 2010-05-13 |
| US11752158B2 (en) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2403107T3 (es) | Método de tratamiento de insuficiencia y deficiencia de vitamina D | |
| ES2401205T3 (es) | Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo | |
| ES3044311T3 (en) | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease | |
| ES2904546T3 (es) | Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3 | |
| ES2809477T3 (es) | Formulación de vitamina D de liberación modificada estabilizada y método de administración de la misma | |
| ES2791535T3 (es) | Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D | |
| ES3036821T3 (en) | Methods and compositions for reducing parathyroid levels | |
| ES2712740T3 (es) | Tratamiento de afecciones asociadas con eotaxina incrementada con 25-hidroxivitamina D3 | |
| US10046000B2 (en) | Use of 2-methylene-19-nor-(20S)-1α,25-Dihydroxyvitamin D3 to treat and prevent secondary hyperparathyroidism in a subject having renal failure | |
| Sawarkar et al. | Transdermal vitamin D supplementation—A potential vitamin D deficiency treatment | |
| WO1995017889A1 (en) | Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis | |
| JPS63107929A (ja) | 新規ビタミンｄ↓３誘導体を有効成分とする医薬 | |
| US9814736B2 (en) | Use of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism | |
| HK1205936B (zh) | 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物 | |
| US10105375B2 (en) | Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism | |
| Srikanth et al. | Correction of secondary hyperparathyroidism after distal gastric bypass using oral high dose vitamin D, calcitriol and calcium replacement | |
| JPH04279522A (ja) | 血清カルシウム濃度調整薬 |